Is there a relationship between gliflozins and acute pancreatitis? Evidence-based analysis

Background: acute pancreatitis is a sudden inflammation of the pancreas with the possibility of presenting severe complications. Diabetes is a chronic metabolic disease, the cause of a large part of global morbidity and mortality. Approximately 90 % of patients with diabetes suffer from type II diabetes. Several studies were carried out in this regard, and with fairly large samples in quantitative terms. Within the treatment of type II diabetes there are hypoglycemic agents, of which there is a group called gliflozins or also inhibitors of sodium-glucose cotransporter 2 (SGLT2is) such as canagliflozin and empagliflozin. Methods: a systematic review of the literature available in databases such as PubMed was carried out, carrying out specific investigations to identify case reports of acute pancreatitis associated with the use of gliflozin. For this, an exhaustive reading of all the available articles was carried out. Results: of the 4 articles analyzed, the average incidence of pancreatitis in patients who used gliflozin was 0,38 %. Conclusion: we conclude that it is not possible to establish a causal relationship between the use of gliflozin and acute pancreatitis